Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Study Evaluating the Antiviral Activity and Safety of 3 Month Fuzeon Induction With an Optimized Background Antiretroviral Regimen Versus OB Alone, in Fuzeon-naive HIV-1 Infected Patients With Virological Failure.

NCT00615134 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00615134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Study Evaluating the Antiviral Activity and Safety of 3 Month Fuzeon Induction With an Optimized Background Antiretroviral Regimen Versus OB Alone, in Fuzeon-naive HIV-1 Infected Patients With Virological Failure.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2011
Enrollment
29 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections